TY - JOUR
T1 - HPV vaccination and HPV-related malignancies
T2 - impact, strategies and optimizations toward global immunization coverage
AU - Giannone, Gaia
AU - Giuliano, Anna R.
AU - Bandini, Marco
AU - Marandino, Laura
AU - Raggi, Daniele
AU - Earle, Wayne
AU - Ayres, Benjamin
AU - Pettaway, Curtis A.
AU - McNeish, Iain A.
AU - Spiess, Philippe E.
AU - Necchi, Andrea
N1 - Funding Information:
G. Giannone is a recipient of a translational research fellowship from The European Society of Medical Oncology (ESMO).
Funding Information:
G. Giannone: educational activities for Mylan. A.R. Giuliano: Consulting for Merck & CO, Inc Grant/research Support from Merck & CO, Inc, Moderna. L. Marandino: research funding from Astra Zeneca. B. Ayres: Consulting for Cepheid, Honoraria from Olympus, Honoraria from Kyowa Kirin, Member of ASCO/EAU penile cancer guidelines panel, Orchid Male Cancer charity trustee, Education co-lead Global Society Rare Genitourinary tumors. C. Pettaway: Editorial Consultant for “UpToDate” Penile Cancer Series, Wolter Kluwers. I.A. McNeish: Advisory boards and speaker fees for Astra Zeneca, Clovis Oncology, GSK/Tesaro, Roche, OncoC4, Epsila Bio, Theolytics and Duke St Bio. Institutional grant income from Astra Zeneca. P.E. Spiess: Vice-chair of the NCCN bladder and penile cancer panel, President of the Global Society of Rare Genitourinary Tumors, Member of the ASCO/EAU Guideline panel. A. Necchi: Consulting for Merck, Astra Zeneca, Janssen, Incyte, Roche, Rainier Therapeutics, Clovis Oncology, Bayer, and Astellas/Seattle Genetics, Ferring, Immunomedics. Grant/Research support from Merck, Ipsen, and Astra Zeneca. Travel expenses/Honoraria from Roche, Merck, Astra Zeneca, and Janssen. All the remaining authors have no conflicts of interest to declare.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/12
Y1 - 2022/12
N2 - HPV-related diseases represent a major cause of morbidity and mortality, although effective HPV vaccines are available, potentially allowing for the elimination of these malignancies. Historically, most of the available literature has focused on cervical cancer, the fourth commonest cause of cancer-related death worldwide, whose incidence is heterogeneous mirroring the inequitable distribution of facilities for screening and treatment and vaccination programs. A broader vision of HPV vaccination impact is needed to understand the potential effect of a global high immunization coverage on both cervical cancer and other HPV-associated malignancies, in women and men. Five HPV vaccines are currently available, all inducing antibody response against the most frequent high-risk HPV types (HPV16 and 18). They are safe and strongly reduce the incidence of HPV-related diseases in clinical trials and in real-world studies, among both women and men. Therefore, WHO has set an ambitious goal for the global elimination of cervical cancer. The WHO global strategy has been launched to accomplish this goal and is supported by multiple organizations, governments, and donors, aiming at vaccinating 90% of young girls worldwide by 2030. In this setting, it is vital to optimize vaccination programs, with a focus on delivery approaches, target populations, increasing financial support, and awareness. In conclusion, HPV vaccination is safe and effective and can lead to the first case of cancer elimination worldwide. A sustained joint effort is fundamental for this goal to be reached, with optimization of this strategy and adaptation of vaccination programs to country-specific infrastructure.
AB - HPV-related diseases represent a major cause of morbidity and mortality, although effective HPV vaccines are available, potentially allowing for the elimination of these malignancies. Historically, most of the available literature has focused on cervical cancer, the fourth commonest cause of cancer-related death worldwide, whose incidence is heterogeneous mirroring the inequitable distribution of facilities for screening and treatment and vaccination programs. A broader vision of HPV vaccination impact is needed to understand the potential effect of a global high immunization coverage on both cervical cancer and other HPV-associated malignancies, in women and men. Five HPV vaccines are currently available, all inducing antibody response against the most frequent high-risk HPV types (HPV16 and 18). They are safe and strongly reduce the incidence of HPV-related diseases in clinical trials and in real-world studies, among both women and men. Therefore, WHO has set an ambitious goal for the global elimination of cervical cancer. The WHO global strategy has been launched to accomplish this goal and is supported by multiple organizations, governments, and donors, aiming at vaccinating 90% of young girls worldwide by 2030. In this setting, it is vital to optimize vaccination programs, with a focus on delivery approaches, target populations, increasing financial support, and awareness. In conclusion, HPV vaccination is safe and effective and can lead to the first case of cancer elimination worldwide. A sustained joint effort is fundamental for this goal to be reached, with optimization of this strategy and adaptation of vaccination programs to country-specific infrastructure.
KW - Cervical cancer
KW - Human papillomavirus
KW - Penile cancer
KW - Tumor prevention
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85140855823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140855823&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2022.102467
DO - 10.1016/j.ctrv.2022.102467
M3 - Review article
C2 - 36265336
AN - SCOPUS:85140855823
SN - 0305-7372
VL - 111
JO - Cancer treatment reviews
JF - Cancer treatment reviews
M1 - 102467
ER -